Immunization safety priority project at the World Health Organization

Seminars in Pediatric Infectious Diseases

Volumn 14, Issue 3, 2003, Pages 233-239

  Duclos, Philippe ^a   Delo, Alison ^b   Aguado, Teresa ^b   Bilous, Julian ^b   Birmingham, Maureen ^b   Kieny, Marie Paule ^b   Milstien, Julie ^b   Wood, David ^b   Tarantola, Daniel ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

DRUG SAFETY; HEALTH PROGRAM; IMMUNIZATION; INJECTION; QUALITY CONTROL; REVIEW; WORLD HEALTH ORGANIZATION;

EID: 0043022138     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1045-1870(03)00038-4     Document Type: Article

References (40)

1. Simonsen L, Kane A, Lloyd J, et al: Unsafe injections in the developing world and transmission of blood borne pathogens: A review. Bull World Health Organ 77:789-800, 1999
2. Hutin YJF, Duclos P, Hogerzeil H, et al: Unsterile injections and emergence of human pathogens. Lancet 359:2280, 2002
3. Gangarosa EJ, Galazka AM, Wolfe CR, et al: Impact of antivaccine movements on pertussis control: The untold story. Lancet 351:356-361, 1998
4. Stratton K, Gable A, Shetty P, et al: Immunization Safety Review. Measles-Mumps-Rubella Vaccine and Autism. Immunization Safety review Committee, Board on Health Promotion and Disease Prevention, Institute of Medicine, Washington, DC, National Academy Press, 2001
5. MMR vaccination coverage in the United Kingdom. Commun Dis Rep CDR Wkly [serial online only] 2001. Available from: URL: http://www.phls.org.uk/publications/cdr/archkre/news/news0401.htmlMMR
6. Pareek M, Pattison H: The two-dose measles, mumps, and rubella (MMR) immunization schedule: Factors affecting maternal intention to vaccinate. Br J Gen Pract 50:969-971, 2000
7. Thomas DR, Salmnon RL, King J: Rates of first measles-mumps-rubella immunisation in Wales, United Kingdom. Lancet 351:1927, 1998
8. Kumar S: Polio epidemics hits Uttar Pradesh. BMJ 325:617, 2002
9. Duclos P: Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opin Drug Saf 2:225-231, 2003
10. Rauh L, Schmidt R: Measles immunization with killed virus vaccine. Am J Dis Child 109:232-237, 1965
11. Ehresman K, Lynfield R, Danila R, et al: Intussusception among recipients of rotavirus vaccine - United Sates, 1998-1999. MMWR 48:577-580, 1999
12. Global Advisory Committee on Vaccine Safety 20-21 June 2002. Wkly Epidemiol Rec 77:389-394, 2003
13. WHO: Vaccines, Immunization and Biologicals: 2000-2003 Strategy. WHO/V&B/00.02. Geneva, Switzerland, Department of Vaccines and Biologicals, April 2000
14. WHO: Safe Injection Global Network (SIGN) Initial Meeting Report. WHO/DCT/00.1. Geneva, Switzerland, 2000
15. WHO: Best infection control practices for skin-piercing intradermal, subcutaneous, and intramuscular needle injections. WHO/BCT/DCT/01.02. Geneva, Switzerland, November 2001
16. WHO-UNICEF-UNFPA: Safety of injections. A joint statement on the use of auto-disable syringes in immunization services. WHO/V&B/99.25. Geneva, Switzerland, December 1999
17. Julia's review article summarizing experience with assessments
18. Health-care waste management. Available at: http://www.healthcarewaste.org. Accessed May 25, 2003
19. WHO: Tool for the assessment of injection safety. WHO/V&B/01.30, WHO/BCT/01.02. Geneva, Switzerland, August 2001
20. Dellepiane N, Griffiths E, Milstien JB: New challenges in assuring vaccine quality. Bull World Health Organ 78:155-162, 2000
21. Jodar L, Clements CJ, Duclos P, et al: Ensuring vaccine safety in immunization programmes - A WHO perspective. Vaccine 19:1594-1605, 2001
22. WHO: Annex 6 Recommendations and guidelines for biological substances used in medicine and other documents. Technical Report Series 904:104-107, 2002
23. Butel JS: Simian virus 40, poliovirus vaccines, and human cancer: Research progress versus media and public interests. Bull World Health Organ 78:195-198, 2000
24. th Report. WHO Technical Report Series 889. Geneva, Switzerland, 1999
25. Sangar D, Pipkin PA, Wood DJ, et: Examination of poliovirus vaccine preparations for SV40 sequences. Biologicals 27:1-10, 1999
26. th Report. WHO Technical Report Series 897. Geneva, Switzerland, 2000, pp 61-66
27. WHO: Ensuring the quality of vaccines at country level. Guidelines for health staff. WHO/V&B/02.16. Geneva, Switzerland, March 2002
28. Vall Mayans M, Robertson SE, Duclos P: Adverse events monitoring as a routine component of vaccine clinical trials: Evidence from the WHO Vaccine Trial registry. Bull World Health Organ 78:1166-1167, 2000
29. Ioannidis JP, Lau J: Completeness of safety reporting in randomised trials. An evaluation of 7 medical areas. JAMA 285: 437-443, 2001
30. WHO guidelines on clinical evaluation of vaccines: Regulatory expectations Expert Committee on Biological Standardization Technical Report Series, annex, (in press), 2003
31. WHO: Supplementary information on vaccine safety. Part 1: Field issues. WHO/V&B/00.24. Geneva, Switzerland, Department of Vaccines and Biologicals, July 2000
32. WHO: Supplementary information on vaccine safety. Part 2: Background rates of adverse events following immunization. WHO/V&B/00.36. Geneva, Switzerland, Department of Vaccines and Biologicals, World Health Organization, Geneva, Switzerland, December 2000
33. WHO: Immunization Safety Surveillance. Guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization. Immunization Focus. Manila, Philippines, Regional Office for the Western Pacific, 1999
34. Mehta U, Milstien JB, Duclos P, et al: Developing a national system for dealing with adverse events following immunization. Bull World Health Organ 78:170-177, 2000
35. Oral poliovirus vaccine (OPV) and intussusception. Wkly Epidemiol Rec 75:345-347, 2000
36. Vaccine Safety Advisory Committee. Vaccine Safety. Wkly Epidemiol Rec 41:227-228, 1999
37. Global Advisory Committee on Vaccine Safety. Causality assessment of adverse events following immunization. Wkly Epidemiol Rec 76:85-88, 2001
38. Bonhoeffer J, Kohl K, Chen R, et al. The Brighton Collaboration: Addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 21: 298-302, 2002
39. The Brighton Collaboration: Setting standards in vaccine safety. Available at: www.brightoncollaboration.org. Accessed May 25, 2003
40. Index of vaccines. http://www.who.int/vaccines-surveillance/ispp.index.html. Accessed May 25, 2003